PHF6与JAK3突变协同驱动T-ALL进展
该研究在白血病患者与小鼠模型中探讨JAK3激活与PHF6失活的协同作用,发现JAK/STAT与PHF6共突变患者平均生存期更短;Phf6缺失通过抑制Bai1-Mdm2-P53通路促进JAK3M511I诱导的T-ALL进展,且不依赖JAK3/STAT5通路;JAK3抑制剂托法替尼联合MDM2抑制剂idasanutlin可减轻体内白血病负荷。
要点
- JAK/STAT与PHF6共突变患者平均生存期短于其他患者。
- Phf6缺失经Bai1-Mdm2-P53通路促进JAK3M511I诱导的T-ALL进展。
- 托法替尼联合idasanutlin可降低Phf6 KO与JAK3M511I白血病负荷。
核心结论
- PHF6与JAK3突变协同驱动T-ALL进展,联合JAK3与MDM2抑制剂可能使PHF6与JAK3共突变T-ALL患者获益。
研究设计与样本
- 在白血病患者与小鼠模型中检验JAK3激活与PHF6失活的协同作用。
主要发现
- JAK/STAT与PHF6共突变患者平均生存期短于其他患者。
- Phf6缺失通过抑制Bai1-Mdm2-P53通路促进JAK3M511I诱导的T-ALL进展。
- 该促进作用不依赖JAK3/STAT5信号通路。
- 托法替尼联合idasanutlin减少体内Phf6 KO与JAK3M511I白血病负荷。
关键数值与推荐
- JAK3抑制剂为tofacitinib,MDM2抑制剂为idasanutlin,二者联合用于体内治疗。
临床怎么用
- 对携带PHF6与JAK3共突变的T-ALL患者,可考虑JAK3抑制剂联合MDM2抑制剂的治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
T-cell acute lymphoblastic leukemia (T-ALL) is a malignant hematologic disease caused by gene mutations in T-cell progenitors. As an important epigenetic regulator, PHF6 mutations frequently coexist with JAK3 mutations in T-ALL patients. However, the role(s) of PHF6 mutations in JAK3-driven leukemia remain unclear. Here, the cooperation between JAK3 activation and PHF6 inactivation is examined in leukemia patients and in mice models. We found that the average survival time is shorter in patients with JAK/STAT and PHF6 comutation than that in other patients, suggesting a potential role of PHF6 in leukemia progression. We subsequently found that Phf6 deficiency promotes JAK3M511I-induced T-ALL progression in mice by inhibiting the Bai1-Mdm2-P53 signaling pathway, which is independent of the JAK3/STAT5 signaling pathway. Furthermore, combination therapy with a JAK3 inhibitor (tofacitinib) and a MDM2 inhibitor (idasanutlin) reduces the Phf6 KO and JAK3M511I leukemia burden in vivo. Taken together, our study suggests that combined treatment with JAK3 and MDM2 inhibitors may potentially increase the drug benefit for T-ALL patients with PHF6 and JAK3 comutation.
引用
- Yuan S, Wang X, Hou S, et al. PHF6 and JAK3 mutations cooperate to drive T-cell acute lymphoblastic leukemia progression. Leukemia. 2021. PMID: 34465864. doi:10.1038/s41375-021-01392-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。